Company Overview and News

98
Box Office Top 20: 'Incredibes 2' record inches higher

2018-06-18 nzherald.co.nz
LOS ANGELES (AP) — Disney and Pixar's record-breaking opening of "Incredibles 2" is even bigger than initially expected. According to final totals Monday from the studios, the animated sequel grossed a massive $182.7 million in its first three days in theaters — a record opening for animated movies by almost $50 million.
VIA LGF CCV CMCSA TWX CCZ SNEJF TWC AMCX VIAB CCV.CL LGF.A SNE LGF.B CMCSK DIS

2
Lions Gate: Theatrical Slate Quality Is A Risk

2018-06-18 seekingalpha
Starz helps the company, but management is not off the hook in terms of programming a viable, commercial film slate.
LGF LGF.A LGF.B

208
Look for Prospective Suitors to Call On Lions Gate Entertainment Corp.

2018-06-15 investorplace
Lions Gate Entertainment Corp. (USA) (NYSE:LGF.A,)(NYSE:LGF.B) is seeing a move upward on the approved merger of AT&T Inc. (NYSE:T) and Time Warner Inc (NYSE:TWX). With takeover approval, Lions Gate stock has gained interest on the theory that it too will become a takeover target. Media providers have targeted content companies to boost earnings amid declining profitability in their core industries.
FOX TMUSP LGF TMUS CCV CMCSA TWX NFLX CCZ TWC VZA S AMZN T CCV.CL VZ LGF.A LGF.B FOXA CMCSK DIS

9
Lions Gate: Dissecting The Large Upside Opportunity

2018-06-15 seekingalpha
Lions Gate's stock has ripped higher this week on news that that AT&T-Time Warner merger has been approved.
FOX LGF TWX LGF.A LGF.B TWC FOXA

328
Apple and Amazon Don’t Need to Buy Hollywood - Bloomberg

2018-06-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CBS FB DISH LGF CBS.A CCV CMCSA TWX NFLX CCZ GOOG TWC CBS.WD CCV.CL GOOGL AAPL LGF.A LGF.B CPV CMCSK

2
Lionsgate buys majority stake in 3 Arts, production company behind 30 Rock, Silicon Valley - MarketWatch

2018-05-30 marketwatch
Lions Gate Entertainment Corp. LGF.A, +0.98% LGF.B, +0.72% said Wednesday it has acquired a majority stake in talent management and production company 3 Arts Entertainment. 3 Arts is the company behind a roster of directors, producers, actors, writers and comedians, and TV production including It's Always Sunny in Philadelphia, Man With A Plan, 30 Rock, King of the Hill, The Office, Parks and Recreation, Marlon, Brooklyn Nine Nine, The Mindy Project, Champions, Master of None, Unbreakable Kimmy Schmidt, Insecure, American Vandal, and Silicon Valley.
LGF LGF.A LGF.B

2
Lions Gate Entertainment Corp. Stock Was Up on Earnings Beat

2018-05-25 investorplace
Lions Gate Entertainment Corp. (NYSE:LGF.A) reported its latest quarterly earnings results after the bell Thursday and topped Wall Street’s expectations on the earnings and revenue fronts.
LGF LGF.A LGF.B

281
SNE Stock: Sony Corp (ADR) Is This Decade’s Underappreciated Turnaround | InvestorPlace

2018-05-21 investorplace
Among the so-called recovery stories, Sony Corp (ADR) (NYSE:SNE) is one of the more intriguing, and frustrating. Last year, SNE stock turned in a massive performance, delivering 60% returns to long-embattled shareholders. This followed a fairly solid 15% haul in 2016.
CBS LGF CBS.A BC94 SMSN SNEJF CBS.WD AAPL LGF.A SNE MSFT LGF.B CPV DIS SMSD

94
Lions Gate (LGF.A) to Report Q4 Earnings: What's in Store?

2018-05-21 zacks
Lions Gate Entertainment Corp. (LGF.A - Free Report) is set to report fiscal fourth-quarter 2018 results on May 24. Lions Gate’s adjusted earnings came in at 48 cents per share compared with the year-ago earnings of 20 cents. Earnings also surpassed the Zacks Consensus Estimate of 41 cents.
LGF LGF.A LGF.B NTAP DXC NTNX ATUS

98
Box Office Top 20: 'Avengers' holds at No. 1 for third week

2018-05-15 nzherald.co.nz
LOS ANGELES (AP) — "Avengers: Infinity War" topped the charts for the third weekend in a row, adding $62.1 million to its domestic grosses.
VIA LGF CCV CMCSA TWX CCZ SNEJF TWC AMCX VIAB CCV.CL LGF.A SNE LGF.B CMCSK DIS

102
AMC Networks: Q1 Wasn't That Good - But It Looks Good Enough For Now

2018-05-14 seekingalpha
As a leveraged play on the future of content, AMCX has big risk - and big reward.
CBS DISCB LGF DISCA CBS.A TWX DISCK TWC CBS.WD AMCX LGF.A LGF.B CPV MSGN DISC

30
MOVES-JPMorgan poaches Wells Fargo banker for entertainment group -sources

2018-05-14 reuters
(Reuters) - JPMorgan Chase & Co (JPM.N) has hired Reginald Lang, the head of media investment banking at Wells Fargo & Co (WFC.N), to work for its entertainment industries group, which provides financing to TV and film studios, people familiar with the matter said.
WFC WFCNP WFC.WS LGF WFC.PRL ENTMF VLRSY WFC.PRJ VRL VLRDF WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN LGF.A LGF.B VLRDY WFC.PRY WFC.PRX WFC.PRW WFC.PRV ETO

137
What Will Comcast Corporation Buy Next? It’s Sky or Die

2018-05-09 investorplace
In the battle between the media titans, Walt Disney Co (NYSE:DIS) appears to have the upper hand against Comcast Corporation (NASDAQ:CMCSA). Both have placed substantial bids for Twenty-First Century Fox Inc (NASDAQ:FOXA), as acquiring it aligns with each competitor’s long-term strategy. That said, Fox shareholders prefer Disney. If this deal is finalized, what will Comcast Corporation buy next?
CBS FOX LGF CBS.A CCV CMCSA NFLX CCZ CBS.WD CCV.CL LGF.A LGF.B CPV FOXA CMCSK DIS

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 535919401